The company is selling approximately 8.93 million common shares at $37.50 each. To accommodate demand, underwriters hold a 30-day option to acquire an additional 1.6 million shares at the same price point, excluding standard commissions. For specific investors, Enliven is substituting common stock with pre-funded warrants for up to 1.73 million shares.

Managed by a syndicate including Jefferies, Goldman Sachs, Morgan Stanley, and Barclays, the transaction is slated to close around Monday. This capital injection follows a period of rapid valuation growth for the firm, which has seen its market presence expand aggressively throughout the year.